The maintenance of a Buy rating and a $58 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence among investors and potentially lead to a positive short-term impact on Mirum Pharmaceuticals' stock price. The reaffirmation of the price target suggests that the analyst sees continued upside potential in the stock, which could influence investor sentiment positively.